Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Mumps Vaccine (MumpsVax) Market Revenue Growth Supported By A CAGR Of % Through 2030
The historical expansion was largely driven by elevated rates of mumps outbreaks, the implementation of standard childhood immunization schedules, the proven efficacy of live attenuated vaccines, enforced public health vaccination policies, and the subsequent reduction in disease prevalence following widespread vaccination efforts.
The projected increase during the forecast period is driven by the necessity to stop new outbreaks from reappearing, more rigorous school vaccination mandates, greater worldwide immunization coverage, a priority on sustaining herd immunity, and enhanced public health monitoring. Key developments shaping the forecast period involve the ongoing need for multi-disease vaccines, a strong emphasis on childhood vaccination initiatives, persistent application in epidemic response efforts, incorporation into official national vaccination plans, and a focus on achieving lasting immunity across populations.
Download A Free Sample Report For Comprehensive Market Insights:
Mumps Vaccine (MumpsVax) Market Demand Drivers: What Is Fueling Industry Growth?
The growing prevalence of infectious diseases is anticipated to drive the expansion of the mumps vaccine (mumpsvax) market in the future. Infectious diseases are caused by pathogenic microorganisms like viruses, bacteria, fungi, or parasites, and they can spread from person to person or via contaminated environments. This rise in infectious disease cases is mainly fueled by urbanization, climate shifts, globalization, and evolving human demographics and behaviors, all of which facilitate the spread and emergence of pathogens. Mumpsvax, a vaccine designed to prevent mumps—an infectious disease caused by the mumps virus—is often incorporated into the MMR (measles, mumps, rubella) immunization. For example, as reported in August 2024 by the UK Health Security Agency, a government agency based in the United Kingdom, the West Midlands region had the highest number of measles cases in 2023, totaling 160 (44%), followed by London with 122 cases (33%). Notably, children under 10 made up 63% of all cases, amounting to 232. Measles activity surged toward the end of the year, with 157 new cases recorded in December compared to just 45 in November. Consequently, the increasing occurrence of infectious diseases is boosting the mumps vaccine (mumpsvax) market.
Rising healthcare spending is set to accelerate growth in the mumps vaccine (mumpsvax) market moving ahead. Healthcare expenditure covers the total funds allocated to health-related goods and services, such as personal care, preventive measures, and public health initiatives, all intended to enhance health outcomes over a given timeframe. This increase in healthcare costs stems from factors like an aging population, chronic illnesses, advanced medical technologies, high drug prices, inefficient payment systems, and heightened demand for services. The impact of rising healthcare expenditure on mumpsvax involves increased investment in vaccination programs, which can enhance vaccine accessibility and result in improved public health through higher mumps immunization rates. By way of illustration, in May 2024, data from the Office for National Statistics, a UK government body, showed that total healthcare expenditure grew by 5.6% in nominal terms between 2022 and 2023, compared to a 0.9% growth rate in 2022. Furthermore, long-term health and social care spending rose by 2.8% in real terms in 2022. Thus, the climb in healthcare expenditure is fueling the mumps vaccine (mumpsvax) market.
A surge in clinical trial activity is expected to propel the mumps vaccine (mumpsvax) market forward in the coming period. Clinical trials are essential for advancing knowledge and treatment of conditions like Acute Spinal Cord Injury (SCI). Mumpsvax offers targeted immunity against the mumps virus, aiding clinical trials by acting as a dependable tool for assessing vaccine effectiveness, safety, and immune responses, especially in studies concerning viral infections and pediatric immunization strategies. For instance, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, stated that the total number of clinical trials started in the UK increased from 411 in 2022 to 426 in 2023. As a result, the growing number of clinical trials is driving the mumps vaccine (mumpsvax) market.
Mumps Vaccine (MumpsVax) Market Segment Landscape: Which Areas Lead Market Development?
The mumps vaccine (mumpsvax) market covered in this report is segmented –
1) By Product Type: Monovalent, Combinational, Divalent, Trivalent, Other Product Types
2) By Age Group: Pediatric, Adult
3) By Distribution Channels: Hospital pharmacies, Drug Stores, Retail Pharmacies
4) By End-User: Pediatric Clinic, Hospitals, Non-Governmental Organization (NGOs), Other End-Users
Mumps Vaccine (MumpsVax) Market Industry Leaders And Market Competition
Major companies operating in the mumps vaccine (mumpsvax) market are Merck & Co. Inc., GlaxoSmithKline plc
Access The Complete Mumps Vaccine (MumpsVax) Market Report:
Mumps Vaccine (MumpsVax) Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the mumps vaccine (mumpsvax) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mumps vaccine (mumpsvax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model